BioMed Central Impact Factor

The values below use the current 2025 Journal Impact Factor values from the 2026 Journal Citation Reports release in the local Manusights JCR master export. Treat this as a fast planning table. For grant, CV, promotion, or formal institutional use, verify the exact title and ISSN in Journal Citation Reports.

Do not build a year-over-year BioMed Central trend from the whole portfolio. The portfolio adds, retires, renames, and repositions journals, so a single trend line would be misleading. The most common exact-title fallback in this query family is BMC Medicine, which has its own JIF history.

For that exact journal, the current 8.7 JIF is up from 8.3 in the 2024 data year and down from the COVID-era 12.5 peak in the 2023 data year. That is a BMC Medicine trend, not a BioMed Central portfolio trend.

If your query is biomedcentral impact factor, use this trend only after you confirm that the real target is BMC Medicine. If the target is BMC Public Health, BMC Cancer, BMC Biology, Molecular Cancer, Microbiome, or another BMC title, verify that exact title instead.

The current number is only one part of a submission decision. Record the formal metric separately from the author-facing logistics.

For BMC Medicine specifically, the operational portal is Editorial Manager, and the exact journal ISSN is 1741-7015. For BioMed Central portfolio searches, those details matter because they force the lookup back to an exact title instead of a publisher brand.

Do not read the table as a single BMC ladder. It mixes fields with very different citation behavior. A 5.4 JIF in biology, a 4.4 JIF in public health, and a 3.8 JIF in dentistry do not mean the same thing for author strategy.

The safer read is:

• High-JIF BMC portfolio titles such as Journal of Hematology & Oncology, Molecular Cancer, Molecular Neurodegeneration, Microbiome, Genome Medicine, and Implementation Science are selective field leaders.
• BMC Medicine is the flagship broad clinical-medicine title in the BMC portfolio, but it is not the same as BioMed Central as a whole.
• BMC specialty journals can be better targets than higher-JIF broad journals when the manuscript's real audience is narrow and applied.
• BMC series titles often publish solid open-access work, but their editorial bars differ sharply by field, article type, and reporting requirements.

The most common author mistake is to see the BMC brand and assume a uniform editorial standard. That is wrong. The publisher brand tells you the platform and open-access model. The journal title tells you the audience, metric context, and submission risk.

For every BMC or BioMed Central title, record the evidence in this order:

1. Exact journal title and ISSN.
2. Current JCR release year and underlying metric year.
3. 2025 Journal Impact Factor from the 2026 JCR release.
4. JCR category and quartile.
5. Whether the source is Clarivate, Springer Nature, SCImago, or another secondary directory.
6. The journal page date or access date.
7. Any APC or submission-fee value separately from the citation metric.

That separation prevents two common errors: calling the publisher portfolio a journal, and treating a Scopus/SJR value as the official Journal Impact Factor.

In Manusights pre-submission checks for BMC and BioMed Central targets, the failure pattern is usually not "the author picked a journal with too low an impact factor." It is that the manuscript uses the wrong BMC title as a proxy for the right audience.

Three patterns show up repeatedly:

Portfolio-name targeting instead of journal-title targeting. Authors write "BMC journal" in the plan, then compare BMC Medicine, BMC Public Health, BMC Cancer, and BMC Bioinformatics as if the brand were the audience. Editors do not evaluate the portfolio. They evaluate whether the manuscript fits the specific journal.

Impact-factor laddering across unrelated fields. A paper can look stronger on a spreadsheet when it targets a higher-JIF BMC title, but weaker to reviewers when its methods, reporting standard, or reader group belongs in a specialty journal. Category fit beats raw JIF when the alternatives sit in different fields.

Missing open-access budget and reporting checks. Many BMC journals are fully open access and have article-processing charges, reporting-guideline requirements, data-availability expectations, and transfer options. A target is not ready until the APC, checklist, data, ethics, and article type are all checked against the exact journal page.

If you are comparing BMC titles, a journal-fit check can test whether the manuscript belongs in BMC Medicine, a specialty BMC journal, or a non-BMC alternative before you submit.

• The exact BMC journal's scope matches the manuscript's primary reader.
• The current JIF and quartile are competitive inside the manuscript's field, not just impressive across fields.
• Your article type is accepted by the journal.
• The open-access fee, waiver, or institutional agreement is clear before submission.
• Your reporting checklist, ethics statement, data availability, and limitations are ready for editorial screening.